Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference
03 1월 2024 - 11:00PM
Business Wire
Azitra, Inc. (NYSE American: AZTR), a clinical-stage
biopharmaceutical company focused on developing innovative
therapies for precision dermatology, today announced that
management will present at the Dermatology Summit 2024, on Sunday,
January 7, 2024 at 12:55pm PT and Biotech Showcase 2024, Monday,
January 8, 2024 at 3:30pm PT, alongside the J.P. Morgan 42nd Annual
Healthcare Conference.
Dermatology Summit – January 7, 2024
Format:
Azitra Inc., Corporate Presentation
Date/Time:
January 7th, 12:55 PM PT
Participant:
Travis Whitfill, Chief Operating
Officer
Location:
Hyatt Regency, San Francisco
Biotech Showcase – January 8, 2024
Format:
Azitra Inc., Corporate Presentation
Date/Time:
January 8th, 3:30 PM PT
Participant:
Francisco Salva, Chief Executive
Officer
Location:
Hilton San Francisco Union Square
(Yosemite A)
Webcast Link:
Register here
For more information or to schedule a one-on-one meeting with
management contact your conference representative or email
James@HaydenIR.com.
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical
company focused on developing innovative therapies for precision
dermatology using engineered proteins and topical live
biotherapeutic products. The Company has built a proprietary
platform that includes a microbial library comprised of
approximately 1,500 unique bacterial strains that can be screened
for unique therapeutic characteristics. The platform is augmented
by artificial intelligence and machine learning technology that
analyzes, predicts and helps screen the Company's library of
strains for drug like molecules. The Company's initial focus is on
the development of genetically engineered strains of Staphylococcus
epidermidis, or S. epidermidis, which the Company considers to be
an optimal therapeutic candidate species for engineering of
dermatologic therapies. For more information, please visit
https://azitrainc.com/.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. These statements may be identified by words such
as "aims," "anticipates," "believes," "could," "estimates,"
"expects," "forecasts," "goal," "intends," "may," "plans,"
"possible," "potential," "seeks," "will," and variations of these
words or similar expressions that are intended to identify
forward-looking statements. Any such statements in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements. These forward-looking statements
include, without limitation, statements regarding the expected
timing of the presentation of data from the Phase 1b study of
ATR-12, the filing of an IND application, and the presentation of
data from our Phase 1b for ATR-04, the IND filing for ATR-01, the
timing of having a signed license agreement with Bayer, and
statements about our clinical and pre-clinical programs, and
corporate and clinical/pre-clinical strategies.
Any forward-looking statements in this press release are based
on current expectations, estimates and projections only as of the
date of this release and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to that we may fail to successfully complete
our Phase 1b trial for ATR-12 and pre-clinical studies of other
product candidates and obtain required approval before
commercialization; our product candidates may not be effective;
there may be delays in regulatory approval or changes in regulatory
framework that are out of our control; our estimation of
addressable markets of our product candidates may be inaccurate; we
may fail to timely raise additional required funding; more
efficient competitors or more effective competing treatment may
emerge; we may be involved in disputes surrounding the use of our
intellectual property crucial to our success; we may not be able to
attract and retain key employees and qualified personnel; earlier
study results may not be predictive of later stage study outcomes;
and we are dependent on third-parties for some or all aspects of
our product manufacturing, research and preclinical and clinical
testing. Additional risks concerning Azitra's programs and
operations are described in its registration statement on Form S-1,
which is on file with the SEC, and in its most recent quarterly
report on Form 10-Q to be filed with the SEC. Azitra explicitly
disclaims any obligation to update any forward-looking statements
except to the extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240103099883/en/
Norman Staskey Chief Financial Officer staskey@azitra.com
Hayden IR James Carbonara (646)-755-7412 james@haydenir.com
Azitra (AMEX:AZTR)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Azitra (AMEX:AZTR)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024